이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Cullinan Therapeutics 과거 수익 실적

과거 기준 확인 0/6

Cullinan Therapeutics의 수입은 연평균 -17.5%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 15.5%의 비율로 증가했습니다. 매출은 연평균 128.5%의 비율로 감소해 왔습니다.

주요 정보

-17.5%

수익 성장률

63.6%

EPS 성장률

Biotechs 산업 성장	17.0%
매출 성장률	-128.5%
자기자본 수익률	-31.6%
순이익	n/a
최근 수익 업데이트	31 Mar 2024

최근 과거 실적 업데이트

업데이트 없음

Recent updates

Checking Into Cullinan Therapeutics

Jun 09

Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth

Apr 23

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Jun 24

Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

Mar 05

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Oct 08

Cullinan Oncology: Hub-And-Spoke Business Model For Drug Development

Jun 30

Cullinan Oncology (CGEM) Presents At 2021 ASCO Annual Virtual Meeting - Slideshow

Jun 05

Cullinan initiated Buy at H.C. Wainwright on pipeline strength

Feb 02

수익 및 비용 분석

Cullinan Therapeutics 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqGS:CGEM 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Mar 24	0	-132	44	127
31 Dec 23	0	-153	42	148
30 Sep 23	0	-156	43	135
30 Jun 23	0	-142	42	120
31 Mar 23	0	65	43	120
31 Dec 22	0	111	40	92
30 Sep 22	0	105	40	92
30 Jun 22	0	113	36	85
31 Mar 22	0	-78	32	70
31 Dec 21	19	-66	29	58
30 Sep 21	19	-61	28	60
30 Jun 21	19	-54	24	57
31 Mar 21	19	-47	21	51
31 Dec 20	0	-52	17	43
30 Sep 20	0	-28	6	24
30 Jun 20	0	-25	6	19
31 Mar 20	0	-21	6	17
31 Dec 19	0	-21	5	17

양질의 수익: CGEM 은(는) 현재 수익성이 없습니다.

이익 마진 증가: CGEM 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: CGEM 은(는) 수익성이 없으며 지난 5년 동안 연간 17.5% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 CGEM 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: CGEM 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( -14.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: CGEM 현재 수익성이 없기 때문에 마이너스 자본 수익률( -31.55% )을 갖습니다.

Cullinan Therapeutics 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Recent updates

Independent Director exercised options to buy US$402k worth of stock.

Checking Into Cullinan Therapeutics

Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib

Independent Director exercised options to buy US$2.4m worth of stock.

Consensus EPS estimates upgraded to US$3.01 loss

Cullinan Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Cullinan Therapeutics, Inc. Announces Board Changes

Chief Scientific Officer notifies of intention to sell stock

Consensus revenue estimates increase by 19%

Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial Officer

Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth

Price target increased by 13% to US$28.71

Cullinan Oncology, Inc. announced that it expects to receive $280.000024 million in funding

Cullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024

Cullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024

Chief Business Officer notifies of intention to sell stock

New minor risk - Shareholder dilution

Cullinan Oncology, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

Cullinan Oncology, Inc. to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

Price target decreased by 11% to US$25.25

New minor risk - Profitability

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc. Announces the Launch of the REZILIENT3 Trial

Investor sentiment improves as stock rises 17%

High number of new and inexperienced directors

Chief Development Officer notifies of intention to sell stock

Investor sentiment improves as stock rises 16%

Cullinan Oncology, Inc. Announces First Clinical Data from its Phase 1 Study of CLN-619 in Patients with Advanced Solid Tumors

Cullinan Oncology, Inc. Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, Novel T-Cell Engager for Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Investor sentiment deteriorated over the past week

Chief Development Officer notifies of intention to sell stock

Price target decreased to US$34.00

Cullinan Oncology Appoints of David P. Ryan to Its Board of Directors

Investor sentiment improved over the past week

Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years

Cullinan Oncology: One Of The Leaders In Cancer Treatment Development

Cullinan Oncology grants stock options for 125.7K shares

Cullinan Oncology, Inc. Appoints Jacquelyn Sumer as Chief Legal Officer

Insider recently sold US$712k worth of stock

Chief Business Officer notifies of intention to sell stock

Chief Business Officer notifies of intention to sell stock

Cullinan Oncology, Inc.(NasdaqGS:CGEM) dropped from Russell 2000 Growth Index

Insider recently sold US$1.3m worth of stock

Taiho Pharmaceutical Co., Ltd. completed the acquisition of Cullinan Pearl Corp from Cullinan Oncology, Inc. (NasdaqGS:CGEM).

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

President recently bought US$100k worth of stock

Insider recently sold US$4.0m worth of stock

Price target decreased to US$39.25

Forecast to breakeven in 2022

Taiho Pharmaceutical Co., Ltd. entered into a Share Purchase Agreement to acquire Cullinan Pearl Corp from Cullinan Oncology, Inc. (NasdaqGS:CGEM) for approximately $400 million.

Cullinan Oncology, Inc., Annual General Meeting, Jun 22, 2022

Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients

Cullinan Oncology, Inc. to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio At American Association for Cancer Research 2022

Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

Cullinan Oncology, Inc. Announces Management Appointments

Price target decreased to US$47.75

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Cln-081 for the Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Strategic Advisor notifies of intention to sell stock

Cullinan Oncology, Inc. Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients

CFO & Treasurer exercised options and sold US$166k worth of stock

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Chief Development Officer of Biologics exercised options and sold US$81k worth of stock

CFO & Treasurer exercised options and sold US$363k worth of stock

Insider recently sold US$815k worth of stock

Chief Development Officer of Biologics notifies of intention to sell stock

Insider notifies of intention to sell stock

Insider recently sold US$753k worth of stock

Cullinan Oncology: Hub-And-Spoke Business Model For Drug Development

Cullinan Oncology, Inc. Receives FDA Clearance of Investigational New Drug (IND) Application for CLN-619, a Novel MICA/B-targeted Antibody for the Treatment of Solid Tumors

Cullinan Oncology, Inc. Receives Investigational New Drug Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML

Cullinan Oncology Announces Phase 1/2A Interim Data for Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients

Cullinan Oncology (CGEM) Presents At 2021 ASCO Annual Virtual Meeting - Slideshow

Cullinan Oncology, Inc. to Provide CLN-081 Clinical Update At ASCO 2021

Cullinan Management, Inc. Announces Business Update

Cullinan initiated Buy at H.C. Wainwright on pipeline strength

Cullinan Management, Inc. has completed an IPO in the amount of $249.9 million.